![Moderna on X: "Today, we shared positive pre-clinical data demonstrating our ability to combine 6 mRNAs against 3 different respiratory viruses in 1 vaccine: COVID-19 booster + Flu booster + RSV booster. # Moderna on X: "Today, we shared positive pre-clinical data demonstrating our ability to combine 6 mRNAs against 3 different respiratory viruses in 1 vaccine: COVID-19 booster + Flu booster + RSV booster. #](https://pbs.twimg.com/media/E-2be3DXIAIFcoo.jpg)
Moderna on X: "Today, we shared positive pre-clinical data demonstrating our ability to combine 6 mRNAs against 3 different respiratory viruses in 1 vaccine: COVID-19 booster + Flu booster + RSV booster. #
![Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice - ScienceDirect Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0264410X21014353-gr3.jpg)
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice - ScienceDirect
![Study highlights the importance of bivalent mRNA booster vaccination in populations at high risk of severe COVID-19 Study highlights the importance of bivalent mRNA booster vaccination in populations at high risk of severe COVID-19](https://d2jx2rerrg6sh3.cloudfront.net/images/news/ImageForNews_745226_16817225096615479.jpg)
Study highlights the importance of bivalent mRNA booster vaccination in populations at high risk of severe COVID-19
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
![Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ... Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...](https://www.cdc.gov/mmwr/volumes/72/wr/social-media/mm7205e1_BivalentVECurrentSublineages_IMAGE_25Jan2023_1200x675-medium.jpg?_=95835)
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...
![Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis | Nature Medicine Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01527-y/MediaObjects/41591_2021_1527_Fig4_HTML.png)
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis | Nature Medicine
![Moderna on X: "A 50 µg #booster dose of our first bivalent booster #vaccine candidate, mRNA-1273.211, demonstrated superiority against Beta, Delta and #Omicron variants of concern one month after administration, and superiority Moderna on X: "A 50 µg #booster dose of our first bivalent booster #vaccine candidate, mRNA-1273.211, demonstrated superiority against Beta, Delta and #Omicron variants of concern one month after administration, and superiority](https://pbs.twimg.com/media/FQtOfg9WQAYB92h.jpg:large)
Moderna on X: "A 50 µg #booster dose of our first bivalent booster #vaccine candidate, mRNA-1273.211, demonstrated superiority against Beta, Delta and #Omicron variants of concern one month after administration, and superiority
![Study: Booster dose of mRNA COVID vaccine prompts strong T cell response in immunocompromised patients Study: Booster dose of mRNA COVID vaccine prompts strong T cell response in immunocompromised patients](https://scx2.b-cdn.net/gfx/news/hires/2023/swedish-study-booster.jpg)
Study: Booster dose of mRNA COVID vaccine prompts strong T cell response in immunocompromised patients
![Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study - The Lancet Respiratory Medicine Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/asset/cb26e910-dc14-4b32-a123-110b22c44f1e/gr1.jpg)
Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study - The Lancet Respiratory Medicine
CDC - COVID-19 BOOSTER UPDATE: Everyone ages 18+ is eligible for a COVID-19 booster. If you got an mRNA vaccine, either Pfizer-BioNTech or Moderna, you may get a booster dose 6 months
![Three mRNA COVID-19 vaccine doses very effective in protecting against emergency department visits and hospitalizations associated with Omicron and Delta variants Three mRNA COVID-19 vaccine doses very effective in protecting against emergency department visits and hospitalizations associated with Omicron and Delta variants](https://www.regenstrief.org/wp-content/uploads/2022/01/grannis-mmw-01-21-22-web-02-scaled-1.jpg)
Three mRNA COVID-19 vaccine doses very effective in protecting against emergency department visits and hospitalizations associated with Omicron and Delta variants
![Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis | Nature Medicine Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01527-y/MediaObjects/41591_2021_1527_Fig1_HTML.png)
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis | Nature Medicine
Centers for Disease Control and Prevention on LinkedIn: CDC recommends Novavax's non-mRNA booster for people ages 18 and older…
![Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study - The Lancet Infectious Diseases Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/ee130977-a19d-4087-8be9-e8c163aab599/gr1.gif)
Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study - The Lancet Infectious Diseases
![Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/683be916-2b6a-4719-b001-feea7e4130e9/gr1.jpg)